Read Summary

The Phase 3 KEYNOTE-119 trial evaluating Merck’s Keytruda (pembrolizumab) as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy (capecitabine, eribulin, gemcitabine or vinorelbine), the company announced Monday.
Reuters Health Information

Print Friendly, PDF & Email